Oxidative stress is an early hallmark in neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. However, the critical biochemical effector mechanisms of oxidative neurotoxicity have remained surprisingly elusive. In screening various peroxides and potential substrates of oxidation for their effect on neuronal survival, we observed that intramembrane compounds were significantly more active than aqueous or amphiphilic compounds. To better understand this result, we synthesized a series of competitive and site-specific membrane protein oxidation inhibitors termed aminoacyllipids, whose structures were designed on the basis of amino acids frequently found at the protein-lipid interface of synaptic membrane proteins. Investigating the aminoacyllipids in primary neuronal culture, we found that the targeted protection of transmembrane tyrosine and tryptophan residues was sufficient to prevent neurotoxicity evoked by hydroperoxides, kainic acid, glutathione-depleting drugs, and certain amyloidogenic peptides, but ineffective against non-oxidative inducers of apoptosis such as sphingosine or Akt kinase inhibitors. Thus, the oxidative component of different neurotoxins appears to converge on neuronal membrane proteins, irrespective of the primary mechanism of cellular oxidant generation. Our results indicate the existence of a oneelectron redox cycle based on membrane protein aromatic surface amino acids, whose disturbance or overload leads to excessive membrane protein oxidation and neuronal death. However, comparative investigations of postmortem biomarker oxidation also have inherent limitations. In general, a chemical rationale for the observed structural specificity, if detected, can rarely be assigned. Moreover, it is usually impossible to assess through mere comparison the causal role of an oxidative event in disease progression. A causal Received March 18, 2014; revised manuscript received October 10, 2014; accepted October 24, 2014. Address correspondence and reprint requests to Parvana Hajieva and Christian Behl, Institute for Pathobiochemistry, University Medical Center of the Johannes Gutenberg University, Duesbergweg 6, 55099 Mainz, Germany. E-mail: hajieva@uni-mainz.de and cbehl@uni-mainz.de 1 Present address: Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield S10 2HQ, UK.Abbreviations used: 6-DCFA, 6-carboxy-2 0 ,7 0 -dichlorodihydrofluorescein diacetate bisacetoxymethyl ester; BSO, buthionine sulfoximine; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.